Abstract
The response of bone mass to long-term treatment with estrogen and progesterone in patients with complete androgen-insensitivity syndrome (AIS) is unknown. We report a 17-year-old female patient (karyotype 46 X, Y) with AIS studied during a 4-year period. Bone mineral density (BMD) measured by dual X-ray absorptiometry in lumbar spine and proximal femur was sharply reduced at the initial visit, and remained unchanged during long-term follow-up on hormone replacement therapy with estrogens and progestin. Bone metabolism markers were all in the normal range. The lack of significant increase in BMD highlights the importance of androgens on bone physiology that cannot be balanced in spite of an appropriate estrogenic milieu.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aiman J, Griffin JE, Gazak JM, Wilson JD, MacDonald PC (1979) Androgen insensitivity as a cause of infertility in otherwise normal men. N Engl J Med 300:223–227
Imperato-McGinley J, Canovatchel WJ (1992) Complete androgen insensitivity: pathophysiology, diagnosis, and management. Trends Endocrinol Metab 3:75–81
Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, Riggs BL, Spelsberg TC (1989) Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 86:854–857
Kasperk C, Fitzsimmonds R, Strong D, Mohan S, Jennings J, Wegedal J, Baylink D (1990) Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone. J Clin Endocrinol Metab 71:1322–1329
Vanderschueren D, Van Herck E, Geusens P, Suiker A, Visser W, Chung K, Bouillon R (1994) Androgen resistance and deficiency have different effects on the growing skeleton of the rat. Calcif Tissue Int 55:198–203
Prezelj J, Kocijancic A (1993) Bone mineral density in hyperandrogenic amenorrhoea. Calcif Tissue Int 52:422–424
Slemenda CW, Reister TK, Longcope C, Peacock M, Johnston CC (1994) Significant premenopausal bone loss from the hip: its associations with sex steroids. J Bone Miner Res 9 (suppl 1): s272
Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF Jr (1987) Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Int Med 106: 354–361
Arisaka O, Arisaka M (1991) Effect of testosterone on radial bone mineral density in adolescent male hypogonadism. Acta Paediatr Scand 80:378–380
Finkelstein JS, Neer RM, Biller BMK, Crawford JD, Klibanski A (1992) Osteopenia in men with a history of delayed puberty. N Engl J Med 326:600–604
Mizuno Y, Hosoi T, Inoue S, Ikegami A, Kaneki M, Akedo M, Nakamura T, Ouchi Y, Chang C, Orimo H (1994) Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells. Calcif Tissue Int 54:325–326
Need AL, Morris HA, Wishart JA, Horowitz M, Nordin C (1994) Why do men lose bone?. J Bone Miner Res 9 (suppl 1): s320
Klein RF, Orwoll ES (1994) Bone loss in men: pathogenesis and therapeutic considerations. The Endocrinologist 4:252–269
Finkelstein J, Klibanski A, Neer R (1992) Cortical and trabecular bone density in patients with the complete androgen insensitivity syndrome (AIS). Proc 9th Int Cong of Endocrinology (Nice, France), p 256
Lips P, Asscheman H, Uitewaal P, Netenbos JC, Gooren L (1989) The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexual. J Bone Miner Res 4:657–662
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Muñoz-Torres, M., Jódar, E., Quesada, M. et al. Bone mass in androgen-insensitivity syndrome: Response to hormonal replacement therapy. Calcif Tissue Int 57, 94–96 (1995). https://doi.org/10.1007/BF00298426
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00298426